Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. 1983

A W Mughal, and G N Hortobagyi, and H A Fritsche, and A U Buzdar, and H Y Yap, and G R Blumenschein

Serial plasma carcinoembryonic antigen (CEA) levels were measured in 167 patients with metastatic breast cancer treated with fluorouracil, doxorubicin hydrochloride, and cyclophosphamide (FAC). In 84 patients, the pretreatment CEA value was abnormal. Response rates and remission duration were similar in patients with normal and abnormal pretreatment levels. Carcinoembryonic antigen concentrations decreased in 94% of patients who responded to FAC therapy. The duration of response was 22 months for patients in whom the CEA levels normalized v nine months in those in whom it decreased but never returned to normal. Increasing CEA levels correlated with progressive disease in 87% of patients and preceded clinical evidence of progression in 77%. Serial CEA measurements can monitor response to chemotherapy, provide useful prognostic information of response duration, and detect progressive disease early.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females

Related Publications

A W Mughal, and G N Hortobagyi, and H A Fritsche, and A U Buzdar, and H Y Yap, and G R Blumenschein
May 1978, Annals of internal medicine,
A W Mughal, and G N Hortobagyi, and H A Fritsche, and A U Buzdar, and H Y Yap, and G R Blumenschein
January 1980, Oncodevelopmental biology and medicine : the journal of the International Society for Oncodevelopmental Biology and Medicine,
A W Mughal, and G N Hortobagyi, and H A Fritsche, and A U Buzdar, and H Y Yap, and G R Blumenschein
June 1983, American journal of clinical oncology,
A W Mughal, and G N Hortobagyi, and H A Fritsche, and A U Buzdar, and H Y Yap, and G R Blumenschein
April 1986, Cancer,
A W Mughal, and G N Hortobagyi, and H A Fritsche, and A U Buzdar, and H Y Yap, and G R Blumenschein
January 1984, Archives of internal medicine,
A W Mughal, and G N Hortobagyi, and H A Fritsche, and A U Buzdar, and H Y Yap, and G R Blumenschein
January 1980, Cellular and molecular biology, including cyto-enzymology,
A W Mughal, and G N Hortobagyi, and H A Fritsche, and A U Buzdar, and H Y Yap, and G R Blumenschein
January 1998, Clinical and investigative medicine. Medecine clinique et experimentale,
A W Mughal, and G N Hortobagyi, and H A Fritsche, and A U Buzdar, and H Y Yap, and G R Blumenschein
January 1980, Oncodevelopmental biology and medicine : the journal of the International Society for Oncodevelopmental Biology and Medicine,
A W Mughal, and G N Hortobagyi, and H A Fritsche, and A U Buzdar, and H Y Yap, and G R Blumenschein
November 1980, Surgery, gynecology & obstetrics,
A W Mughal, and G N Hortobagyi, and H A Fritsche, and A U Buzdar, and H Y Yap, and G R Blumenschein
September 1978, Cancer,
Copied contents to your clipboard!